The phenomenon of psychosis, characterized by hallucinations, delusions, and impaired reality testing, often emerges after a prodromal phase marked by subtle cognitive and behavioral changes. Identifying individuals in the “clinical high risk” (CHR) state has allowed clinicians to intervene prior to the full manifestation of psychotic disorders such as schizophrenia. However, the variability in outcomes within this group remains a significant challenge. Some CHR individuals transition to psychosis, while others experience symptom remission or stabilization without progression. This study’s focus on TPAE offers a novel dimension to stratifying risk and predicting clinical trajectories.

TPAE refers to antipsychotic medication exposure before the official baseline assessment in CHR individuals, typically for brief or transient periods. Such exposure—often occurring due to clinical uncertainty or initial symptom management attempts—has historically been considered a confounding factor rather than an informative prognostic marker. The PSYSCAN study team, however, hypothesized that TPAE might reflect underlying pathophysiological or clinical features predictive of subsequent outcomes.

Using a robust cohort derived from multiple international clinical sites within the PSYSCAN consortium, the research team meticulously assessed the prevalence and characteristics of TPAE among CHR patients. Multimodal neuroimaging, including high-resolution structural MRI and functional connectivity analyses, alongside comprehensive symptom assessments and cognitive evaluations, formed the core data streams. Follow-ups over extended time frames enabled capturing real-world transition rates to psychosis or alternative clinical endpoints.

Statistical analyses revealed that TPAE was significantly associated with differential prognostic profiles. Individuals with TPAE exhibited more pronounced neurobiological alterations, particularly in prefrontal and temporal circuits implicated in cognitive control and salience processing. These brain changes closely mirrored clinical symptom severity, suggesting that transient antipsychotic exposure is not merely a treatment artifact but a marker of an intrinsically distinct clinical subtype within the CHR population.

These findings hold profound implications. First, recognizing TPAE as a prognostic specifier equips clinicians with a more refined risk stratification tool, potentially guiding personalized intervention timing and intensity. Early, tailored therapeutic approaches could prevent or delay the transition to full-blown psychosis, minimizing the long-term disability burden. Furthermore, the identification of specific neurobiological alterations associated with TPAE offers promising targets for novel pharmacological or cognitive-rehabilitative treatments designed to modify disease trajectories at a critical juncture.

The study also prompts a reevaluation of clinical practice paradigms. Historically, transient antipsychotic use in at-risk populations was approached with caution due to concerns about medication side effects and uncertain benefits. Demonstrating the prognostic value of TPAE encourages nuanced clinical decision-making, balancing risks and benefits while considering individual patient profiles and symptomatology. Importantly, it underlines the necessity for comprehensive clinical documentation and early neuropsychiatric assessments.

Moreover, the PSYSCAN consortium’s approach exemplifies the power of collaborative, multinational research integrating advanced neurotechnology with clinical psychiatry. This synergy accelerates the translation of complex biological insights into actionable clinical knowledge. By employing standardized neuroimaging protocols and harmonized symptom scales across diverse populations, the study achieves a level of generalizability and methodological rigor often lacking in psychiatric research, which historically suffered from heterogeneity and small sample sizes.

The discovery of TPAE as a prognostic factor also challenges prevailing theoretical models of psychosis development. Traditional frameworks emphasize genetic predisposition and environmental stressors culminating in neurodevelopmental disruptions. The PSYSCAN study suggests that early pharmacological intervention—even if transient—intertwines with underlying pathophysiology to shape future outcomes. This insight invites further exploration of dynamic interactions between treatment exposure and brain plasticity during critical developmental windows.

Future research directions inspired by this work include investigating the mechanistic pathways through which TPAE modulates neurobiological and clinical trajectories. Experimental paradigms examining synaptic remodeling, neurotransmitter system recalibrations, and neuroinflammatory responses in the presence of transient antipsychotic exposure could elucidate causative links. Moreover, artificial intelligence-driven predictive models incorporating TPAE alongside genetic, neuroimaging, and environmental variables may revolutionize individualized risk forecasting.

The implications extend beyond psychosis prediction to broader mental health care systems focused on early detection and prevention. By refining criteria for CHR classification and integrating TPAE status, psychiatric services can optimize resource allocation and reduce unnecessary exposure to potent medications. Educational initiatives targeting clinicians and patients could demystify the rationale behind nuanced intervention strategies, mitigating stigma and promoting adherence.

Importantly, this research underscores the heterogeneity inherent in psychotic disorders and their prodromal phases. The conceptualization of TPAE as a specifier aligns with emerging precision psychiatry paradigms, which emphasize subtyping mental illnesses based on biological and clinical markers rather than broad diagnostic labels alone. Such frameworks promise enhanced therapeutic efficacy and better long-term functional outcomes for affected individuals.

In conclusion, the PSYSCAN consortium’s study on transient pre-baseline antipsychotic exposure profoundly advances the field of psychosis research. It identifies TPAE not as a mere artifact or confounder but as a meaningful clinical and biological indicator predictive of disease progression within a highly vulnerable population. These insights beckon a paradigm shift in early psychosis intervention, the integration of neurobiological markers into everyday clinical workflows, and the pursuit of personalized psychiatry informed by meticulous, multinational research collaboration.

Raballo, Poletti, and Preti’s work represents a vibrant convergence of neuroscience, clinical psychiatry, and data-driven inquiry, illustrating how modern science can unravel lingering mysteries of mental illness. As researchers, clinicians, and policymakers digest these findings, the hope is clear: to translate knowledge into earlier, smarter interventions that change lives and illuminate the path to recovery for those at the precipice of psychosis.

Subject of Research: Transient pre-baseline antipsychotic exposure as a prognostic specifier in clinical high risk for psychosis.

Article Title: Transient pre-baseline antipsychotic exposure (TPAE) is a prognostic specifier in clinical high risk for psychosis: evidence from the PSYSCAN consortium study.

Article References:
Raballo, A., Poletti, M. & Preti, A. Transient pre-baseline antipsychotic exposure (TPAE) is a prognostic specifier in clinical high risk for psychosis: evidence from the PSYSCAN consortium study. Schizophr 11, 119 (2025). https://doi.org/10.1038/s41537-025-00665-3

Image Credits: AI Generated

Schizophrenia and psychotic disorders have long baffled clinicians and neuroscientists alike, partly due to the elusive nature of their biomarkers. Traditional diagnosis heavily relies on clinical interviews and symptomatic ratings, which often delay intervention until the disease has significantly progressed. The novel approach presented in this study leverages circulating levels of NR1 and NR2 receptor subunits, components of the N-methyl-D-aspartate receptor (NMDAR) complex that play critical roles in synaptic transmission and plasticity in the central nervous system.

The researchers employed a cross-sectional design incorporating three distinct cohorts: individuals experiencing their first episode of schizophrenia (FES), those identified as clinical high risk (CHR) for psychosis, and healthy controls (HC). Blood samples were analyzed using enzyme-linked immunosorbent assay (ELISA) to quantify serum NR1 and NR2 concentrations. Cognitive performance was concurrently assessed through the MATRICS Consensus Cognitive Battery (MCCB), a standardized tool evaluating multiple cognitive domains affected in schizophrenia.

Statistical analyses revealed significant differences in serum NR1 levels across all three groups. Strikingly, patients with first-episode schizophrenia exhibited markedly distinct NR1 concentrations compared to both high-risk individuals and healthy controls, suggesting an elevated or dysregulated expression correlating with disease onset. This delineation highlights the potential of NR1 as a discriminator between active psychosis and prodromal states or unaffected individuals.

Meanwhile, serum NR2 levels displayed a notable difference between the CHR and healthy groups, pinpointing NR2 as a sensitive marker potentially reflective of the transitional phase toward psychosis. This finding is particularly relevant as identifying at-risk populations before full-blown clinical symptoms manifest remains a critical challenge in psychiatric medicine. The stability of NR2 concentrations supports its viability as a biomarker in longitudinal monitoring and early intervention strategies.

Delving deeper, the study uncovers intriguing correlations between these biomarkers and cognitive functioning. Within the schizophrenia cohort, elevated NR1 levels were inversely correlated with speed of processing, an essential cognitive domain affecting daily functioning. Similarly, NR2 concentrations negatively correlated with verbal learning abilities, further corroborating the role of NMDAR subunits in cognitive deficits characteristic of schizophrenia.

Conversely, among those at clinical high risk, higher serum NR1 concentrations were positively linked to overall cognitive performance as gauged by the MCCB total score. This paradoxical association may hint at compensatory neurobiological mechanisms or differential receptor regulation during the prodromal phase. Such nuanced insights could pave the way for targeted cognitive therapies tailored to biomarker profiles.

To evaluate the diagnostic utility of these findings, receiver operating characteristic (ROC) curve analyses were conducted. Serum NR2 emerged as a superior discriminator for both FES and CHR groups, boasting area under the curve (AUC) values of 69% and 74%, respectively, coupled with high specificity (85%) albeit moderate sensitivity. Optimal cutoff values for NR2 concentration were established around 32.8 ng/mL, offering a quantifiable threshold for clinical application.

These findings collectively signify a paradigm shift towards objective biochemical markers in psychiatry, transcending traditional symptom-based frameworks. The use of peripheral blood measurements ensures minimally invasive procedures, enhancing practical feasibility in clinical settings. Furthermore, the dual correlation with cognitive domains underscores the functional relevance of these biomarkers beyond mere diagnostic categorization.

Despite the promising implications, the authors emphasize the necessity for larger-scale studies and longitudinal designs to validate these preliminary findings fully. Variabilities in sample size, demographic factors, and assay methodologies warrant cautious interpretation. Additionally, mechanistic investigations exploring the pathophysiological pathways linking NR1 and NR2 alterations to psychotic pathology remain imperative.

Integrating serum NR1 and NR2 concentrations into routine psychiatric evaluation holds transformative potential. Early identification of high-risk individuals could facilitate timely interventions, potentially altering disease trajectories and improving long-term outcomes. Moreover, individualized treatment paradigms based on biomarker profiles may optimize therapeutic efficacy while minimizing side effects.

As neuroscience continues to unravel the molecular intricacies of psychosis, studies like this reinforce the hopeful vision of precision psychiatry. Bridging molecular biomarkers with cognitive phenotypes equips clinicians with powerful tools for diagnosis, prognosis, and personalized care. This research constitutes a significant step toward demystifying the biochemical landscape of schizophrenia and psychosis risk, fostering advancements that may ultimately alleviate the global burden of these debilitating disorders.

In conclusion, serum concentrations of NR1 and NR2 subunits represent promising biomolecular candidates for distinguishing first-episode schizophrenia and clinical high-risk states from healthy individuals. Their correlations with cognitive impairments further validate their clinical relevance, while the relative stability and diagnostic accuracy of NR2 highlight its biomarker potential. While additional research is essential to cement their clinical utility, these findings herald a new era in biomarker-driven psychiatric assessment.

—

Subject of Research: Identification and validation of serum NR1 and NR2 subunits as biomarkers for first-episode schizophrenia and clinical high risk for psychosis, including their relationship with cognitive functions.

Article Title: Serum NR1 and NR2 concentrations in first-episode schizophrenia and clinical high-risk for psychosis

Article References:
Mao, Z., Li, F., Ge, L. et al. Serum NR1 and NR2 concentrations in first-episode schizophrenia and clinical high-risk for psychosis. BMC Psychiatry 25, 493 (2025). https://doi.org/10.1186/s12888-025-06950-w

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-06950-w